Article Text

PDF
SAT0322 Prevalence and Risk Factors for Cognitive Impairment in Systemic Lupus Erythematosus
  1. O. Vera-Lastra,
  2. M. Castrejon,
  3. J. Sepulveda-Delgado,
  4. M.D.P. Cuz-Dominguez,
  5. G. Medina,
  6. L.J. Jara
  1. Internal Medicine, Hospital Especialidades CMN la Raza. Instituto Mexicano Seguro Social, Mexico City, Mexico

Abstract

Background Neuropsychiatric disorders have a high morbidity being cognitive impairment (CI) one of the most frequent syndromes in systemic lupus erythematosus (SLE) which lead to a poor quality of life

Objectives To determine the prevalence and risk factors of CI in patients with systemic lupus erythematosus

Methods Twenty seven patients were selected from a total of 150 patients with SLE. CI was evaluated in all patients by the test of Barcelona (for qualitative evaluation of cognitive state: language, reading, writing, visual recognition, memory and abstraction) and the Montreal cognitive assessment (COCA). The following risk factors were evaluated: SLEDAI, obesity/overweight, systemic arterial hypertension, dyslipidemia, pulses of methylprednisolone, SLIC/ACR, use of benzodiazepine, cyclophosphamide and chloroquine. Statistical analysis: Fisher test, T-test Student and logistical regression.

Results There were 27 SLE patients (25 women and 2 men), mean age 42±14 years) mean disease evolution (10±8.6 years), length of education (11.7±4.2 years). With the test of Barcelona we found that 100% of patients had involvement in at least one item, being the most affected areas: attention in 33%, memory in 52%, analysis synthesis and abstraction in 44.4%. With respect to the MOCA a prevalence of 55.6% (15 of 27) of CI was found. Of these patients 12 of 15 had mild CI and 3 of 15 dementia. We only found that the use of chloroquine conferred protection against cognitive impairment (OR 0.236, CI 0.120–0.692, p<0.003). The other risk factors were not significant: dyslipidemia (OR 8.5, CI 0.508–143, p= NS), SLIC/ACR (OR 6.3, CI 0.64–109.7), obesity/overweight (OR 0.407, CI 0.02–5-2, systemic arterial hypertension (OR 0.782, CI 0.031–754), pulses of methylprednisolone (1. 85, CI 0.64- 18.119), use of cyclophosphamide (OR 0. 327, CI 0.115–7.056), among others.

Conclusions We found a high prevalence of cognitive impairment being the use of chloroquine a protective factor. It is important to recognize these patients in order to offer them a medical alternative with a psychological rehabilitation.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.